Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bicalutamide

Criteria

Inclusion Criteria:

• Prostate cancer in the early stage of disease

• Prostate removed and/or radiation therapy to the prostate area

Exclusion Criteria:

• Previous systemic therapy for prostate cancer

• Previous history of another form of cancer (not prostate) within 5 years of study start.